Bright Minds Biosciences Inc.

NASDAQ•DRUG

CEO: Mr. Ian McDonald

セクター: Healthcare

業種: Biotechnology

上場日: 2021-03-22

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

連絡先情報

19 Vestry Street, New York, NY, 10013, United States

N/A

brightmindsbio.com

時価総額

$596.63M

PER (TTM)

-40.2

18.8

配当利回り

52週高値

$123.75

52週安値

$23.18

52週レンジ

53%

順位54Top 78.1%

2.7

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 2.7 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q1 2026 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.70+0.00%

直近4四半期の推移

フリーCF

-$4.17M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

FY2025 40-F Filed Annual Report filed for fiscal year ended September 30, 2025, incorporating required audited financial statements and MD&A exhibits.

Share Count Confirmed Confirmed 7,635,789 common shares outstanding as of the September 30, 2025 period close date for reporting purposes.

Internal Controls Effective Management evaluation confirmed disclosure controls and financial reporting controls were effective as of September 30, 2025.

NASDAQ Listed Security Common Shares trade on NASDAQ Capital Market under symbol DRUG; Company operates as a foreign private issuer.

リスク要因

Financial Data External Key financial performance metrics are not detailed here, relying entirely on incorporated exhibits like the MD&A and AIF.

IFRS vs US GAAP Financial statements prepared under IFRS standards, which differ from US GAAP, impacting direct comparability for US investors.

Forward-Looking Statements Risk Forward-looking statements involve known and unknown risks; actual future results could materially differ from expectations.

Governance Disclosure Reliance NASDAQ compliance relies on Canadian home country practice accommodations for executive sessions and committee composition rules.

見通し

Governance Structure Maintained Audit, Compensation, and N&CG Committees maintain full independence status based on NASDAQ Rule 5605 criteria for all members.

EGC Status Benefits Company remains an Emerging Growth Company, thus exempt from providing auditor attestation for internal control over financial reporting.

No Material Amendments No material amendment was made to the adopted Code of Business Conduct and Ethics during the fiscal year 2025.

CSE Compliance Intent Company intends to follow CSE rules regarding shareholder approval for dilutive issuances and fundamental change transactions.

同業比較

売上高 (TTM)

RIGL

$294.28M

+64.1%

ADCT

$75.21M

+6.4%

ETON

$70.32M

+102.8%

粗利益率 (最新四半期)

KRRO

100.0%

+0.0pp

ALMS

100.0%

+0.0pp

ADCT

92.7%

-2.7pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ALMS	$2.81B	-11.4	-75.5%	7.7%
ANNX	$617.11M	-3.7	-92.3%	11.8%
DRUG	$596.63M	-40.2	-28.5%	0.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月21日

EPS:-$1.34

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし